查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
生物相似药单株抗体的全球市场的分析 (2022年～2032年)
市场调查报告书
商品编码
1109040

生物相似药单株抗体的全球市场的分析 (2022年～2032年)

Biosimilar Monoclonal Antibodies Market Report 2022-2032
出版日期: | 出版商: Visiongain Reports Ltd. | 英文 461 Pages | 商品交期: 最快1-2个工作天内

价格

生物相似药单株抗体的全球市场，2021年是40亿8,700万美金，在预测期间 (2022年～2032年) 预计以23.5％的年复合成长率成长。

本报告提供全球生物相似药单株抗体的市场相关分析，产品概要和市场基本结构、最新形势，主要的促进、阻碍因素，市场规模的估计值、预测值 (2022年～2032年)，各类型、各用途、各化合物及各地区、主要国家详细趋势，主要企业的简介，COVID-19影响与復苏情境等彙整资讯，为您概述为以下内容。

目录

第1章 分析概要

第2章 摘要整理

第3章 生物相似药单株抗体的产业结构

  • 市场与技术的背景
  • 生物相似药的生命週期
  • 生物相似药的开发
  • 细胞株的开发与选择
  • 大肠菌细胞
  • 哺乳类细胞
  • 生物相似药的製造
  • 生物相似药的前临床试验与检验
  • 临床试验
  • 法规当局的核准
  • 药物安全检测/核准后的监测

第4章 全球市场动态

  • 推动市场要素
    • 领导生物相似药:成本效益高的医疗保健的未来
    • 单株抗体 (mAb):广泛疾病的治疗中的主要治疗方法
  • 阻碍市场要素
    • 单株抗体的复杂度生物相似药製造
    • 生物相似药法规途径的几个重要特征还未确定
  • 全球市场的机会
    • 本地企业的多国籍生物相似药企业的销售额提高的支援
    • 新兴国家，提供盈利高的成长机会
  • 全球市场的课题
    • 医药品的高成本:重要的问题
    • 预测不可能的法规情形
    • 生物相似药企业应对基础设施的必要性
  • PEST分析

第5章 世界生物相似药单株抗体市场分析

  • 全球市场预测
  • 全球市场规模:估计值、预测值
    • COVID-19前的市场情境

第6章 全球生物相似药单株抗体市场:各地区

  • COVID-19前的市场情境
  • COVID-19后的市场情境 (V字型/Ｕ字型/W字型/L字型的復苏分析)

第7章 全球生物相似药单株抗体市场:各类型

  • 合成化学品
  • 生物医药品

第8章 全球生物相似药单株抗体市场:各用途

  • 慢性疾病、自体免疫疾病
  • 肿瘤

第9章 全球生物相似药单株抗体市场:各化合物

  • Infliximab
  • Rituximab
  • Abciximab
  • Trastuzumab
  • Adalimumab
  • Bevacizumab

第10章 北美的生物相似药单株抗体市场分析

  • 北美的生物相似药单株抗体市场 (以金额为准)
    • COVID-19前的市场情境
    • COVID-19后的市场情境 (V字型/Ｕ字型/W字型/L字型的復苏分析)
  • 北美的生物相似药单株抗体市场:各国
  • 美国的生物相似药单株抗体市场分析
  • 加拿大的生物相似药单株抗体市场分析
  • 墨西哥的生物相似药单株抗体市场分析
  • 北美的生物相似药单株抗体市场:各类型
  • 北美的生物相似药单株抗体市场:各用途
  • 北美的生物相似药单株抗体市场:各化合物

第11章 欧洲的生物相似药单株抗体市场分析

  • 欧洲市场预测
  • 欧洲的生物相似药单株抗体市场 (以金额为准)
  • 欧洲的生物相似药单株抗体市场:各国
  • 德国的生物相似药单株抗体市场分析
  • 英国的生物相似药单株抗体市场分析
  • 法国的生物相似药单株抗体市场分析
  • 义大利的生物相似药单株抗体市场分析
  • 西班牙的生物相似药单株抗体市场分析
  • 其他的欧洲各国的生物相似药单株抗体市场分析
  • 欧洲的生物相似药单株抗体市场:各类型
  • 欧洲的生物相似药单株抗体市场:各用途
  • 欧洲的生物相似药单株抗体市场:各化合物

第12章 亚太地区的生物相似药单株抗体市场分析

  • 亚太地区市场预测
  • 亚太地区的生物相似药单株抗体市场 (以金额为准)
  • 亚太地区的生物相似药单株抗体市场:各国
  • 中国的生物相似药单株抗体市场分析
  • 印度的生物相似药单株抗体市场分析
  • 日本的生物相似药单株抗体市场分析
  • 韩国的生物相似药单株抗体市场分析
  • 澳洲的生物相似药单株抗体市场分析
  • 其他的亚太地区各国的生物相似药单株抗体市场分析
  • 亚太地区的生物相似药单株抗体市场:各类型
  • 亚太地区的生物相似药单株抗体市场:各用途
  • 亚太地区的生物相似药单株抗体市场:各化合物

第13章 南美、中东、非洲的生物相似药单株抗体市场分析

  • 南美、中东、非洲市场预测
  • 南美、中东、非洲的生物相似药单株抗体市场 (以金额为准)
  • 南美、中东、非洲的生物相似药单株抗体市场:各国
  • 南美、中东、非洲的生物相似药单株抗体市场:各类型
  • 南美、中东、非洲的生物相似药单株抗体市场:各用途
  • 南美、中东、非洲的生物相似药单株抗体市场:各化合物
  • 巴西的生物相似药单株抗体市场分析
  • 南非的生物相似药单株抗体市场分析
  • 沙乌地阿拉伯的生物相似药单株抗体市场分析
  • 土耳其的生物相似药单株抗体市场分析
  • 阿拉伯联合大公国的生物相似药单株抗体市场分析
  • 其他的南美、中东、非洲各国的生物相似药单株抗体市场分析

第14章 企业简介

  • Pfizer Inc.
    • 概述
    • 企业概要
    • 财务简介
    • 产品基准
    • 近几年趋势
  • Novartis AG
  • Boehringer Ingelheim GmbH
  • Intas Pharmaceuticals Ltd.
  • Amgen
  • Biocon
  • Celltrion Healthcare Co. Ltd
  • Dong-A Socio Holdings
  • Dr. Reddy's Laboratories Ltd
  • 3SBio
  • Allergan (AbbVie Inc.)
  • Genor BioPharma Co. Ltd.
  • Reliance Life Sciences
  • Torrent Pharmaceuticals
  • BIOCAD

第15章 结论、建议

Product Code: PHA1181

The global biosimilar monoclonal antibodies market was valued at US$4,087 million in 2021 and is projected to grow at a CAGR of 23.5% during the forecast period 2022-2032.

The Biosimilar Monoclonal Antibodies Market Report 2022-2032: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Increasing Demand for Cost-Effective Biosimilars

The utilization of biological agents in the manufacturing of biopharma products increases complexity. As a result, biosimilars are not "exact" replicas of their biological counterparts despite being similar in function and intended use. Cancer, rheumatoid arthritis, diabetes, and anemia are just a few of the conditions that are treated with the help of branded biologics and biosimilars. The cost of biosimilar pharmaceuticals is lower than that of branded drugs because they are exact replicas of their branded counterparts.

The rise in advanced monoclonal antibody production, rising geriatric population, and high prevalence of chronic diseases like cancer, renal failure, rheumatoid, psoriasis, diabetes, and others are all factors contributing to the growth of the global biosimilar monoclonal antibodies market. Additionally, the increasing number of mAbs whose patents are about to expire will probably increase market growth potential in the years to come.

What Questions Should You Ask before Buying a Market Research Report?

  • How is the biosimilar monoclonal antibodies market evolving?
  • What is driving and restraining the biosimilar monoclonal antibodies market?
  • How will each biosimilar monoclonal antibodies submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2032?
  • How will the market shares for each biosimilar monoclonal antibodies submarket develop from 2022 to 2032?
  • What will be the main driver for the overall market from 2022 to 2032?
  • Will leading biosimilar monoclonal antibodies markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
  • How will the market shares of the national markets change by 2032 and which geographical region will lead the market in 2032?
  • Who are the leading players and what are their prospects over the forecast period?
  • What are the biosimilar monoclonal antibodies projects for these leading companies?
  • How will the industry evolve during the period between 2020 and 2032? What are the implications of biosimilar monoclonal antibodies projects taking place now and over the next 10 years?
  • Is there a greater need for product commercialization to further scale the biosimilar monoclonal antibodies market?
  • Where is the biosimilar monoclonal antibodies market heading and how can you ensure you are at the forefront of the market?
  • What are the best investment options for new product and service lines?
  • What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the biosimilar monoclonal antibodies market today, and over the next 10 years:

  • Our 461-page report provides 238 tables and 272 charts/graphs exclusively to you.
  • The report highlights key lucrative areas in the industry so you can target them - NOW.
  • It contains in-depth analysis of global, regional and national sales and growth.
  • It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the biosimilar monoclonal antibodies market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2032 and other analyses reveal commercial prospects

  • In addition to revenue forecasting to 2032, our new study provides you with recent results, growth rates, and market shares.
  • You will find original analyses, with business outlooks and developments.
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising biosimilar monoclonal antibodies prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, "V", "L", "W" and "U" are discussed in this report.

Segments Covered in the Report

Market Segment by Type

  • Synthetic Chemicals
  • Biopharmaceuticals

Market Segment by Application

  • Chronic & Autoimmune Diseases
  • Oncology Diseases
  • Other Applications

Market Segment by Compound

  • Infliximab
  • Rituximab
  • Abciximab
  • Trastuzumab
  • Adalimumab
  • Bevacizumab

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for four regional and 20 leading national markets:

North America

  • U.S.
  • Canada
  • Mexico

Europe

  • Germany
  • Spain
  • United Kingdom
  • France
  • Italy
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific

LAMEA

  • Brazil
  • Turkey
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Latin America

The report also includes profiles and for some of the leading companies in the Biosimilar Monoclonal Antibodies Market, 2022 to 2032, with a focus on this segment of these companies' operations.

Leading companies and the potential for market growth

  • 3SBio Inc.
  • AbbVie Inc. (AbbVie)
  • Amgen Inc.
  • BIOCAD
  • Biocon Limited
  • Boehringer Ingelheim
  • Celltrion Healthcare Co Ltd.
  • Dong-A Socio Holdings
  • Dr. Reddy's Laboratories Ltd
  • Genor Biopharma Holdings Ltd.
  • Intas Pharmaceuticals Ltd.
  • Novartis AG
  • Pfizer Inc.
  • Reliance Industries Limited
  • Torrent Pharmaceuticals Limited

Overall world revenue for Biosimilar Monoclonal Antibodies Market, 2022 to 2032 in terms of value the market will surpass US$4,749 million in 2022, our work calculates. We predict strong revenue growth through to 2032. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Biosimilar Monoclonal Antibodies Market, 2022 to 2032 report help you?

In summary, our 480+ page report provides you with the following knowledge:

  • Revenue forecasts to 2032 for Biosimilar Monoclonal Antibodies Market, 2022 to 2032 Market, with forecasts for type, application, compound and company size, each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.
  • Revenue forecasts to 2032 for four regional and 20 key national markets - See forecasts for the Biosimilar Monoclonal Antibodies Market, 2022 to 2032 market in North America, Europe, Asia-Pacific and LAMEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
  • Prospects for established firms and those seeking to enter the market - including company profiles for 15 of the major companies involved in the Biosimilar Monoclonal Antibodies Market, 2022 to 2032.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Our study is for everybody needing commercial analyses for the Biosimilar Monoclonal Antibodies Market, 2022 to 2032, market-leading companies. You will find data, trends and predictions.

Table of Contents

1 Report Overview

  • 1.1 Introduction to Biosimilar Monoclonal Antibodies Market
  • 1.2 Global Biosimilar Monoclonal Antibodies Market Overview
  • 1.3 What are the Objectives of this Report?
  • 1.4 What is the Scope of the Report?
  • 1.5 Biosimilar Monoclonal Antibodies Market Definition
  • 1.6 Why You Should Read This Report
  • 1.7 What This Report Delivers
  • 1.8 Key Questions Answered By This Analytical Report Include:
  • 1.9 Who is This Report for?
  • 1.10 Research Methodology
    • 1.10.1 Primary Research
    • 1.10.2 Secondary Research
    • 1.10.3 Market Evaluation & Forecasting Methodology
  • 1.11 Frequently Asked Questions (FAQs)
  • 1.12 Associated Reports
  • 1.13 About

2 Executive Summary

  • 2.1 Introduction

3 Biosimilar Monoclonal Antibodies Industry Structure

  • 3.1 Market and Technology Background
  • 3.2 Lifecycle of a Biosimilar Drug
  • 3.3 Development of a Biosimilar
  • 3.4 Cell Line Development and Selection
  • 3.5 E. coli Cells
  • 3.6 Mammalian Cells
  • 3.7 Manufacturing of a Biosimilar
  • 3.8 Preclinical Studies and Validation of a Biosimilar
  • 3.9 Clinical Trials
  • 3.10 Approval by Regulatory Agencies
  • 3.11 Pharmacovigilance/Post-Approval Monitoring

4 Global Market Dynamics

  • 4.1 Market Driving Factors
    • 4.1.1 Biosimilars: Leading the Way to Cost Effective Healthcare
    • 4.1.2 mAbs Will Continue to be a Dominant Therapeutic Modality for Treatment of a Broad Range of Diseases
  • 4.2 Market Restraining Factors
    • 4.2.1 Monoclonal Antibody Complexity and Biosimilar Manufacturing
    • 4.2.2 Several Critical Features of Biosimilar Regulatory Pathway is Yet to be Finalized
  • 4.3 Opportunities in the Global Market
    • 4.3.1 Local Companies Can Help Multinational Biosimilars Companies Improve Sales
    • 4.3.2 Emerging Economies to Offer Lucrative Growth Opportunities
  • 4.4 Challenges in the Global Market
    • 4.4.1 High Cost of Pharmaceuticals Has Become a Key Issue
    • 4.4.2 Unpredictable Regulatory Landscape
    • 4.4.3 Biosimilars Companies Must Address Infrastructure
  • 4.5 PEST Analysis
    • 4.5.1 Political Factors
    • 4.5.2 Economic Factors
    • 4.5.3 Social Factors
    • 4.5.4 Technology Factors

5 Global Biosimilar Monoclonal Antibodies Market Analysis

  • 5.1 Global Market Outlook
  • 5.2 Global Market Size Estimation and Forecast
    • 5.2.1 Pre-COVID-19 Market Scenario

6 Global Biosimilar Monoclonal Antibodies Market by Region

    • 6.1.1 Pre-COVID-19 Market Scenario
    • 6.1.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)

7 Global Biosimilar Monoclonal Antibodies Market by Type

    • 7.1.1 Synthetic Chemicals
    • 7.1.2 Biopharmaceuticals
    • 7.1.3 Pre-COVID-19 Market Scenario
    • 7.1.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)

8 Global Biosimilar Monoclonal Antibodies Market by Application

    • 8.1.1 Chronic & Autoimmune Diseases
    • 8.1.2 Oncology
    • 8.1.3 Pre-COVID-19 Market Scenario
    • 8.1.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)

9 Global Biosimilar Monoclonal Antibodies Market by Compound

    • 9.1.1 Infliximab
    • 9.1.2 Rituximab
    • 9.1.3 Abciximab
    • 9.1.4 Trastuzumab
    • 9.1.5 Adalimumab
    • 9.1.6 Bevacizumab
    • 9.1.7 Pre-COVID-19 Market Scenario
    • 9.1.8 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)

10 North America Biosimilar Monoclonal Antibodies Market Analysis

  • 10.1 North America Biosimilar Monoclonal Antibodies Market by Value
    • 10.1.1 Pre-COVID-19 Market Scenario
    • 10.1.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 10.2 North America Biosimilar Monoclonal Antibodies Market by Country
    • 10.2.1 Pre-COVID-19 Market Scenario
    • 10.2.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 10.3 U.S. Biosimilar Monoclonal Antibodies Market Analysis
    • 10.3.1 FDA Approves First Interchangeable Biosimilar Insulin Product for Treatment of Diabetes
    • 10.3.2 Pre-COVID-19 Market Scenario
    • 10.3.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 10.4 Canada Biosimilar Monoclonal Antibodies Market Analysis
    • 10.4.1 Northwest Territories Becomes Fifth Jurisdiction in Canada to Implement Biosimilar Switching Initiative
    • 10.4.2 CGPA / Biosimilars Canada Statement on COVID-19 and the Supply and Distribution of Generic and Biosimilar Prescription Medicines in Canada
    • 10.4.3 Pre-COVID-19 Market Scenario
    • 10.4.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 10.5 Mexico Biosimilar Monoclonal Antibodies Market Analysis
    • 10.5.1 Mexico: Major Change To The Regulatory Approval System For Biosimilars, Medicines And Medical Devices
    • 10.5.2 Pre-COVID-19 Market Scenario
    • 10.5.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 10.6 North America Biosimilar Monoclonal Antibodies Market by Type
    • 10.6.1 Pre-COVID-19 Market Scenario
    • 10.6.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 10.7 North America Biosimilar Monoclonal Antibodies Market by Application
    • 10.7.1 Pre-COVID-19 Market Scenario
    • 10.7.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 10.8 North America Biosimilar Monoclonal Antibodies Market by Compound
    • 10.8.1 Pre-COVID-19 Market Scenario
    • 10.8.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)

11 Europe Biosimilar Monoclonal Antibodies Market Analysis

  • 11.1 Europe Market Outlook
  • 11.2 Europe Biosimilar Monoclonal Antibodies Market by Value
    • 11.2.1 Pre-COVID-19 Market Scenario
    • 11.2.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 11.3 Europe Biosimilar Monoclonal Antibodies Market by Country
    • 11.3.1 Pre-COVID-19 Market Scenario
    • 11.3.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 11.4 Germany Biosimilar Monoclonal Antibodies Market Analysis
    • 11.4.1 Pre-COVID-19 Market Scenario
    • 11.4.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 11.5 UK Biosimilar Monoclonal Antibodies Market Analysis
    • 11.5.1 Abzena Collaboration
    • 11.5.2 Pre-COVID-19 Market Scenario
    • 11.5.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 11.6 France Biosimilar Monoclonal Antibodies Market Analysis
    • 11.6.1 Pre-COVID-19 Market Scenario
    • 11.6.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 11.7 Italy Biosimilar Monoclonal Antibodies Market Analysis
    • 11.7.1 Pre-COVID-19 Market Scenario
    • 11.7.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 11.8 Spain Biosimilar Monoclonal Antibodies Market Analysis
    • 11.8.1 Bevacizumab Biosimilars Launched in Spain
    • 11.8.2 Pre-COVID-19 Market Scenario
    • 11.8.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 11.9 Rest of Europe Biosimilar Monoclonal Antibodies Market Analysis
    • 11.9.1 Pre-COVID-19 Market Scenario
    • 11.9.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 11.10 Europe Biosimilar Monoclonal Antibodies Market by Type
    • 11.10.1 Pre-COVID-19 Market Scenario
    • 11.10.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 11.11 Europe Biosimilar Monoclonal Antibodies Market by Application
    • 11.11.1 Pre-COVID-19 Market Scenario
    • 11.11.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 11.12 Europe Biosimilar Monoclonal Antibodies Market by Compound
    • 11.12.1 Pre-COVID-19 Market Scenario
    • 11.12.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)

12 Asia-Pacific Biosimilar Monoclonal Antibodies Market Analysis

  • 12.1 Asia-Pacific Market Outlook
  • 12.2 Asia-Pacific Biosimilar Monoclonal Antibodies Market by Value
    • 12.2.1 Pre-COVID-19 Market Scenario
    • 12.2.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 12.3 Asia-Pacific Biosimilar Monoclonal Antibodies Market by Country
    • 12.3.1 Pre-COVID-19 Market Scenarios
    • 12.3.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 12.4 China Biosimilar Monoclonal Antibodies Market Analysis
    • 12.4.1 Pre-COVID-19 Market Scenario
    • 12.4.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 12.5 India Biosimilar Monoclonal Antibodies Market Analysis
    • 12.5.1 Roche's Antibody Cocktail (Casirivimab and Imdevimab) Is Now Available In India, Cipla To Market It Pan-India
    • 12.5.2 Pre-COVID-19 Market Scenario
    • 12.5.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 12.6 Japan Biosimilar Monoclonal Antibodies Market Analysis
    • 12.6.1 Adalimumab Biosimilar Launched in Japan
    • 12.6.2 Pre-COVID-19 Market Scenario
    • 12.6.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 12.7 South Korea Biosimilar Monoclonal Antibodies Market Analysis
    • 12.7.1 Launch Of Bevacizumab Biosimilar Onbevzi in Korea
    • 12.7.2 Pre-COVID-19 Market Scenario
    • 12.7.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 12.8 Australia Biosimilar Monoclonal Antibodies Market Analysis
    • 12.8.1 Pre-COVID-19 Market Scenario
    • 12.8.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 12.9 Rest of Asia-Pacific Biosimilar Monoclonal Antibodies Market Analysis
    • 12.9.1 Pre-COVID-19 Market Scenario
    • 12.9.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 12.10 Asia-Pacific Biosimilar Monoclonal Antibodies Market by Type
    • 12.10.1 Pre-COVID-19 Market Scenario
    • 12.10.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 12.11 Asia-Pacific Biosimilar Monoclonal Antibodies Market by Application
    • 12.11.1 Pre-COVID-19 Market Scenario
    • 12.11.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 12.12 Asia-Pacific Biosimilar Monoclonal Antibodies Market by Compound
    • 12.12.1 Pre-COVID-19 Market Scenario
    • 12.12.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)

13 LAMEA Biosimilar Monoclonal Antibodies Market Analysis

  • 13.1 LAMEA Market Outlook
  • 13.2 LAMEA Biosimilar Monoclonal Antibodies Market by Value
    • 13.2.1 Pre-COVID-19 Market Scenario
    • 13.2.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 13.3 LAMEA Biosimilar Monoclonal Antibodies Market by Country
    • 13.3.1 Pre-COVID-19 Market Scenario
    • 13.3.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 13.4 LAMEA Biosimilar Monoclonal Antibodies Market by Type
    • 13.4.1 Pre-COVID-19 Market Scenario
    • 13.4.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 13.5 LAMEA Biosimilar Monoclonal Antibodies Market by Application
    • 13.5.1 Pre-COVID-19 Market Scenario
    • 13.5.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 13.6 LAMEA Biosimilar Monoclonal Antibodies Market by Compound
    • 13.6.1 Pre-COVID-19 Market Scenario
    • 13.6.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 13.7 Brazil Biosimilar Monoclonal Antibodies Market Analysis
    • 13.7.1 Pre-COVID-19 Market Scenario
    • 13.7.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 13.8 South Africa Biosimilar Monoclonal Antibodies Market Analysis
    • 13.8.1 Pre-COVID-19 Market Scenario
    • 13.8.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 13.9 Saudi Arabia Biosimilar Monoclonal Antibodies Market Analysis
    • 13.9.1 Pre-COVID-19 Market Scenario
    • 13.9.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 13.10 Turkey Biosimilar Monoclonal Antibodies Market Analysis
    • 13.10.1 Pre-COVID-19 Market Scenario
    • 13.10.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 13.11 UAE Biosimilar Monoclonal Antibodies Market Analysis
    • 13.11.1 Pre-COVID-19 Market Scenario
    • 13.11.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 13.12 Rest of LAMEA Biosimilar Monoclonal Antibodies Market Analysis
    • 13.12.1 Pre-COVID-19 Market Scenario
    • 13.12.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)

14 Company Profiles

  • 14.1 Pfizer Inc.
    • 14.1.1 Company Snapshot
    • 14.1.2 Company Overview
    • 14.1.3 Company Financial Profile
    • 14.1.4 Company Product Benchmarking
    • 14.1.5 Company Recent Developments
  • 14.2 Novartis AG
    • 14.2.1 Company Snapshot
    • 14.2.2 Company Overview
    • 14.2.3 Company Financial Profile
    • 14.2.4 Company Product Benchmarking
    • 14.2.5 Company Recent Developments
  • 14.3 Boehringer Ingelheim GmbH
    • 14.3.1 Company Snapshot
    • 14.3.2 Company Overview
    • 14.3.3 Company Financial Profile
    • 14.3.4 Company Product Benchmarking
    • 14.3.5 Company Recent Developments
  • 14.4 Intas Pharmaceuticals Ltd.
    • 14.4.1 Company Snapshot
    • 14.4.2 Company Overview
    • 14.4.3 Company Product Benchmarking
  • 14.5 Amgen
    • 14.5.1 Company Snapshot
    • 14.5.2 Company Overview
    • 14.5.3 Company Financial Profile
    • 14.5.4 Company Product Benchmarking
    • 14.5.5 Company Recent Developments
  • 14.6 Biocon
    • 14.6.1 Company Snapshot
    • 14.6.2 Company Overview
    • 14.6.3 Company Financial Profile
    • 14.6.4 Company Product Benchmarking
    • 14.6.5 Company Recent Developments
  • 14.7 Celltrion Healthcare Co. Ltd
    • 14.7.1 Company Snapshot
    • 14.7.2 Company Overview
    • 14.7.3 Company Financial Profile
    • 14.7.4 Company Product Benchmarking
    • 14.7.5 Company Recent Developments
  • 14.8 Dong-A Socio Holdings
    • 14.8.1 Company Snapshot
    • 14.8.2 Company Overview
    • 14.8.3 Company Financial Profile
    • 14.8.4 Company Product Benchmarking
    • 14.8.5 Company Recent Developments
  • 14.9 Dr. Reddy's Laboratories Ltd
    • 14.9.1 Company Snapshot
    • 14.9.2 Company Overview
    • 14.9.3 Company Financial Profile
    • 14.9.4 Company Product Benchmarking
    • 14.9.5 Company Recent Developments
  • 14.10 3SBio
    • 14.10.1 Company Snapshot
    • 14.10.2 Company Overview
    • 14.10.3 Company Financial Profile
    • 14.10.4 Company Product Benchmarking
    • 14.10.5 Company Recent Developments
  • 14.11 Allergan(AbbVie Inc.)
    • 14.11.1 Company Snapshot
    • 14.11.2 Company Overview
    • 14.11.3 Company Financial Profile
    • 14.11.4 Company Product Benchmarking
    • 14.11.5 Company Recent Developments
  • 14.12 Genor BioPharma Co. Ltd.
    • 14.12.1 Company Snapshot
    • 14.12.2 Company Overview
    • 14.12.3 Company Product Benchmarking
    • 14.12.4 Company Recent Developments
  • 14.13 Reliance Life Sciences
    • 14.13.1 Company Snapshot
    • 14.13.2 Company Overview
    • 14.13.3 Company Product Benchmarking
    • 14.13.4 Company Recent Developments
  • 14.14 Torrent Pharmaceuticals
    • 14.14.1 Company Snapshot
    • 14.14.2 Company Overview
    • 14.14.3 Company Financial Profile
    • 14.14.4 Company Product Benchmarking
    • 14.14.5 Company Recent Developments
  • 14.15 BIOCAD
    • 14.15.1 Company Snapshot
    • 14.15.2 Company Overview
    • 14.15.3 Company Product Benchmarking
    • 14.15.4 Company Recent Developments

15 Conclusion and Recommendations

  • 15.1 Conclusion Summary
  • 15.2 Recommendations for Market Players

List of Tables

  • Table 1. Global Biosimilar Monoclonal Antibodies Market Forecast, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 2. Global Biosimilar Monoclonal Antibodies Market Snapshot, 2022 & 2032 (US$million, CAGR %)
  • Table 3. List of Biosimilars Produced in E. Coli
  • Table 4. List of Biosimilars Produced in Mammalian Cells
  • Table 5. Key Differences in Approval Pathways for Biosimilars, European Union (EU) vs. United Sates (U.S.)
  • Table 6. US Approved Biosimilars
  • Table 7. Biosimilar Monoclonal Antibodies Swot Analysis
  • Table 8. Global Biosimilar Monoclonal Antibodies Market Forecast, 2022-2032 (USD Mn, AGR (%), CAGR (%))
  • Table 9. Global Biosimilar Monoclonal Antibodies Market by Region, 2022-2032 (USD Mn, AGR (%), CAGR (%))
  • Table 10. Global Biosimilar Monoclonal Antibodies Market by Region, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 11. Global Biosimilar Monoclonal Antibodies Market by Region, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 12. Global Biosimilar Monoclonal Antibodies Market by Region, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 13. Global Biosimilar Monoclonal Antibodies Market by Region, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 14. 50 Biopharmaceuticals Products
  • Table 15. Global Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR (%))
  • Table 16. Global Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 17. Global Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 18. Global Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 19. Global Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 20. Global Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR (%))
  • Table 21. Global Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 22. Global Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 23. Global Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 24. Global Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 25. Biosimilar Active Substance Reference Product Company
  • Table 26. Global Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 27. Global Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 28. Global Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 29. Global Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 30. Global Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 31. North America Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 32. North America Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 33. North America Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 34. North America Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 35. North America Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 36. North America Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 37. North America Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 38. North America Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 39. North America Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 40. North America Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 41. US Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 42. US Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 43. US Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 44. US Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 45. US Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 46. Canada Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 47. Canada Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 48. Canada Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 49. Canada Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 50. Canada Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 51. Mexico Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 52. Mexico Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 53. Mexico Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 54. Mexico Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 55. Mexico Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 56. North America Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 57. North America Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 58. North America Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 59. North America Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 60. North America Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 61. North America Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 62. North America Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 63. North America Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 64. North America Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 65. North America Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 66. North America Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 67. North America Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 68. North America Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 69. North America Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 70. North America Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 71. Europe Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 72. Europe Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 73. Europe Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 74. Europe Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 75. Europe Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 76. Europe Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 77. Europe Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 78. Europe Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 79. Europe Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 80. Europe Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 81. Germany Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 82. Germany Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 83. Germany Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 84. Germany Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 85. Germany Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 86. UK Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 87. UK Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 88. UK Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 89. UK Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 90. UK Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 91. France Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 92. France Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 93. France Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 94. France Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 95. France Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 96. Italy Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 97. Italy Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 98. Italy Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 99. Italy Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 100. Italy Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 101. Spain Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 102. Spain Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 103. Spain Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 104. Spain Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 105. Spain Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 106. Rest of Europe Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 107. Rest of Europe Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 108. Rest of Europe Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 109. Rest of Europe Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 110. Rest of Europe Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 111. Europe Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 112. Europe Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 113. Europe Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 114. Europe Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 115. Europe Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 116. Europe Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 117. Europe Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 118. Europe Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 119. Europe Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 120. Europe Biosimilar Monoclonal Antibodies Market by Application, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 121. Europe Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 122. Europe Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 123. Europe Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 124. Europe Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 125. Europe Biosimilar Monoclonal Antibodies Market by Compound, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 126. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 127. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 128. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 129. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 130. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 131. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 132. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 133. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 134. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 135. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Country, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 136. China Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 137. China Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 138. China Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 139. China Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 140. China Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 141. India Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 142. India Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 143. India Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 144. India Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 145. India Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 146. Japan Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 147. Japan Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 148. Japan Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 149. Japan Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 150. Japan Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 151. South Korea Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 152. South Korea Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 153. South Korea Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 154. South Korea Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 155. South Korea Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 156. Australia Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 157. Australia Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 158. Australia Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 159. Australia Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 160. Australia Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 161. Rest of Asia-Pacific Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 162. Rest of Asia-Pacific Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 163. Rest of Asia-Pacific Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 164. Rest of Asia-Pacific Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 165. Rest of Asia-Pacific Biosimilar Monoclonal Antibodies Market by Value, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 166. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 167. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 168. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 169. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))
  • Table 170. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Type, 2022-2032 (USD Mn, AGR (%), CAGR(%))